MAT Resources
REGN-COV2 treatment for COVID-19 patients in NM
Casirivimab and imdevimab (REGN-COV2), which is produced by Regeneron Pharmaceuticals, should be used for outpatient treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 88 pounds) as soon as possible...
Bamlanivimab distribution and treatment prioritization for COVID-19 patients in NM
Recommendations from the NM Medical Advisory Team include, but are not limited to: 1. Bamlanivimab should be distributed to centers with the capacity for intravenous administration and monitoring of outpatients who meet criteria of administration under the FDA...
Convalescent Plasma Treatment for COVID-19 Patients
In August 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of convalescent plasma for the treatment of hospitalized patients with COVID-19.The use of COVID-19 Convalescent Plasma (CCP) collected from individuals who...
Use of remdesivir for the treatment of COVID-19
Remdesivir, under the trade name VEKLURY, should be used according to the prescribing guidelines provided in the FDA approval issued 10/2020.1 The drug is intended for use in patients 12 years of age and older and weighing at least 40 kg for the treatment of...
Summary and Recommendations for Performing Rapid Antigen Tests for Detection of SARS-CoV-2
Rapid antigen tests have recently emerged and offer significant improvement for near patient turn-around-time. Rapid antigen testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) that meet the requirements to...
COVID-19 Frequently Asked Questions
This document outlines a series of responses to COVID-19 frequently asked questions, including information about finding New Mexico COVID-19 cases by county, risk of transmission in certain settings (e.g. dining, gyms), and COVID-19 deaths. Download this resource
Addressing Behavioral Health Needs of New Mexicans during COVID-19 Pandemic
The Mat defines predicted increases in need for behavioral health services during and after the pandemic; defines existing capacity and needed expansion of that capacity; and, outlines needed capacity expansion in an actionable format. Download this resource
Chloroquine or hydroxychloroquine not recommended for treatment of COVID-19
The Medical Advisory Team no longer recommends chloroquine and hydroxychloroquine for the treatment of COVID-19 or SARS-CoV-2 infection, with or without azithromycin. Download this resource
Recommendations for Long-Term Care Facilities related to Facility Transfers and Care Coordination for COVID-19 Positive (and Negative) Residents
The MAT outlines recommendations for Skilled Nursing Facilities, Long-Term Care Facilities, and Assisted Living Facilities related to managing patients/residents who are moving betweenfacilities, including for ancillary and emergency care. Detailed guidance also is...
Review of Current SARS-CoV-2 Test Methods and Recommendations for Increasing Testing Capacity in New Mexico
New data has emerged for existing and expanding test methods for detection of SARS-CoV-2. This document provides a summary and recommendation for some of these methods. Rapid molecular point of care tests have emerged and offer significant improvement for near patient...